Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer.[1] It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.[1]
Tisotumab vedotin was approved for medical use in the United States in September 2021.[1][3] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[4]
^ abcde"Tivdak- tisotumab vedotin injection, powder, for solution". DailyMed. Retrieved 31 October 2021.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Seagen and Genmab Announce FDA Accelerated Approval for Tivdak (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer". Seagen. 20 September 2021. Retrieved 20 September 2021 – via Business Wire.
^Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
Tisotumabvedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal...
brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumabvedotin, being co-developed...
interventions for vaginal bleeding in women with advanced cervical cancer. Tisotumabvedotin (Tivdak) was approved for medical use in the United States in September...
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (AbbVie) Tivdak (tisotumabvedotin) for the treatment of previously treated recurrent or metastatic cervical...
Global Information
This article incorporates text from this source, which is in the public domain.
